GlassScriptPhysician profile
John G Veliath
NPI 1972674414
$4,295.39
in general payments reported to CMS, 2019-2025
30 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $959 · 2021: $1,319 · 2022: $882 · 2023: $475 · 2024: $289 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $708.75 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $410.83 | 2020-2023 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.18 | 2019-2024 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $349.47 | 2020-2024 | Trintellix |
| Abbvie INC. | $313.97 | 2021-2023 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $293.71 | 2020-2024 | Emgality, Jardiance, Mounjaro |
| Daiichi Sankyo INC. | $236.13 | 2020-2023 | Injectafer |
| Pfizer INC. | $228.92 | 2020-2024 | |
| Glaxosmithkline, LLC. | $193.00 | 2020-2022 | |
| Amarin Pharma, INC. | $183.17 | 2019-2021 | |
| Amgen INC. | $137.00 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $134.55 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.00 | 2019-2025 | Xifaxan |
| Horizon Therapeutics Plc | $123.30 | 2020-2022 | |
| Exact Sciences Corporation | $91.81 | 2023-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $64.27 | 2020 | |
| Astellas Pharma US INC | $45.30 | 2025 | Veozah |
| Abbott Laboratories | $35.19 | 2021-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $26.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.05 | 2022 | |
| Axsome Therapeutics, INC. | $22.78 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $21.96 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $19.51 | 2021 | |
| Genentech USA, INC. | $19.06 | 2020 | |
| Merck Sharp & Dohme LLC | $16.38 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.67 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.12 | 2021 | |
| Gilead Sciences, INC. | $13.98 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Veliath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.